- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Eupraxia Pharmaceuticals Projected to Post Earnings on Tuesday
Analysts expect the biotech company to report quarterly results before market open.
Mar. 30, 2026 at 5:10am
Got story updates? Submit your updates here. ›
Eupraxia Pharmaceuticals (NASDAQ:EPRX), a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, is expected to report its quarterly earnings results before the market opens on Tuesday, March 31st. Analysts project the company will announce a loss of $0.13 per share for the quarter.
Why it matters
Eupraxia's earnings report will provide insight into the progress of its lead therapeutic candidate, currently in Phase 1 clinical development for systemic lupus erythematosus. As a clinical-stage biotech, Eupraxia's financial performance and pipeline updates are closely watched by investors seeking exposure to innovative autoimmune disease treatments.
The details
In its previous quarterly report on March 19th, Eupraxia posted a larger-than-expected loss of $0.37 per share, missing analysts' consensus estimate of a $0.16 per share loss. For the current fiscal year, analysts forecast Eupraxia will report a full-year loss of $1 per share, with a similar $1 per share loss projected for the next fiscal year.
- Eupraxia Pharmaceuticals is expected to report earnings before the market opens on Tuesday, March 31st.
- The company last reported quarterly results on Thursday, March 19th.
The players
Eupraxia Pharmaceuticals
A clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases, with a focus on selectively expanding regulatory T cells.
What’s next
Investors will be watching Eupraxia's earnings report closely for updates on the progress of the company's lead drug candidate and any guidance on future clinical milestones.
The takeaway
As a clinical-stage biotech company, Eupraxia's financial performance and pipeline updates are closely monitored by investors seeking exposure to innovative treatments for autoimmune diseases. The upcoming earnings report will provide insight into the company's progress and future prospects.
